人工智能辅助检测淀粉样蛋白相关影像异常:前景与陷阱
本文结合文献综述与早期质量保证经验,评估一款获FDA许可、用于MRI临床工作流中检测淀粉样蛋白相关影像异常(ARIA)的决策支持AI工具;该AI系统提高了对细微ARIA-E和ARIA-H病灶的检测敏感度,但以特异度下降为代价;作者提出将协议统一、专家判读与AI叠加审查相结合的分层工作流。
要点
- AI系统提高细微ARIA-E和ARIA-H病灶检测敏感度,但特异度下降。
- 作者提出协议统一、专家判读与AI叠加审查相结合的分层工作流。
- AI辅助ARIA检测在AD疾病修饰治疗推广中前景大,但需考虑陷阱。
核心结论
- AI辅助ARIA检测是范式转变,在AD疾病修饰治疗更广泛临床使用时有望提升患者安全,但需考虑一些陷阱。
研究设计与样本
- 文献综述与FDA许可AI决策支持工具的早期质量保证经验,该工具用于MRI临床工作流中检测ARIA。
关键影像表现/征象
- ARIA包括微出血和含铁血黄素沉积(ARIA-H)以及水肿(ARIA-E)。
诊断标准与关键数值
- AI系统提高细微ARIA-E和ARIA-H病灶检测敏感度,但特异度下降。
临床应用与阅片要点
- 作者提出将协议统一、专家判读与AI叠加审查相结合的分层工作流。
局限性
- AI系统在提高敏感度的同时导致特异度下降。
- 作者指出AI辅助ARIA检测存在一些需考虑的陷阱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The advent of anti-amyloid therapies (AATs) for Alzheimer disease (AD) has elevated the importance of MRI surveillance for amyloid-related imaging abnormalities (ARIA) such as microhemorrhages and siderosis (ARIA-H) and edema (ARIA-E). We report a literature review and early quality-assurance experience with an FDA-cleared decision support artificial intelligence (AI) tool intended for detection of ARIA in MRI clinical workflows. The AI system improved the sensitivity for detection of subtle ARIA-E and ARIA-H lesions but at the cost of a reduction in specificity. We propose a tiered workflow combining protocol harmonization and expert interpretation with an AI overlay review. AI-assisted ARIA detection is a paradigm shift that offers great promise to enhance patient safety as disease-modifying therapies for AD gain broader clinical use; however, some pitfalls need to be considered.
引用
- Petrella JR, Liu AJ, Wang LA, et al. Artificial Intelligence-Assisted Detection of Amyloid-Related Imaging Abnormalities: Promise and Pitfalls. AJNR Am J Neuroradiol. 2026. PMID: 40738658. doi:10.3174/ajnr.A8946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。